Wells Fargo analyst Tiago Fauth lowered the firm’s price target on Insmed (INSM) to $208 from $234 and keeps an Overweight rating on the shares. The firm believes the pullback in shares creates a good entry point to own the Brinsupri launch and treprostinil palmitil inhalation powder. Arikayce should show good culture conversion, Wells notes, adding that patient-reported outcomes is riskier. Regardless, it thinks shares start to work post the data.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Brinsupri’s Breakout Growth, Robust Balance Sheet, and Upcoming Clinical Catalysts Underpin Buy Rating
- Insmed’s Brinsupri Launch Recasts Growth Outlook
- Insmed price target lowered to $205 from $212 at Stifel
- Insmed: Strengthening Commercial Profile and Favorable Pricing Support Buy Rating and Multi‑Year Growth Outlook
- Insmed director McGirr to step down after 2026 meeting